首页 > 最新文献

Vascular Medicine最新文献

英文 中文
Neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with peripheral artery disease: A systematic review and meta-analysis. 作为外周动脉疾病患者预后生物标志物的中性粒细胞与淋巴细胞比率:系统回顾和荟萃分析。
IF 3 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-12-01 Epub Date: 2024-10-16 DOI: 10.1177/1358863X241281699
Roy B Kurniawan, Paulus P Siahaan, Pandit Bt Saputra, Jannatin N Arnindita, Cornelia G Savitri, Novia N Faizah, Luqman H Andira, Mario D'Oria, J Nugroho Eko Putranto, Firas F Alkaff

Background: The neutrophil-to-lymphocyte ratio (NLR) is a simple and routinely obtained parameter reflecting systemic inflammation, including in peripheral artery disease (PAD).

Methods: This systematic review aimed to assess the role of NLR as a prognostic biomarker in patients with PAD. A systematic search was conducted across PubMed, ScienceDirect, Web of Science, Scopus, ProQuest, EBSCO, and Cochrane. Random-effects meta-analysis was used to pool risk ratios, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). A bivariate model was used to generate summary receiver operating characteristics with the corresponding area under the curve (AUC).

Results: This review included 5243 patients with PAD from nine eligible studies. High NLR corresponded to at least a twofold increased risk of all-cause mortality (ACM), major adverse limb events (MALE), and major adverse cardiovascular events (MACE). NLR's performance was good for predicting 1-year ACM (AUC 0.71 [95% CI: 0.59-0.79], sensitivity 58.2% [95% CI: 45.3-71.0], specificity 72.6% [95% CI: 65.6-79.62], PPV 41.0% [95% CI: 31.2-50.7], NPV 82.7% [95% CI: 74.1-91.3]) and 1-year MALE (AUC 0.78 [95% CI: 0.75-0.80], sensitivity 65.4% [95% CI: 41.6-89.2], specificity 77.7% [95% CI: 71.0-84.3], PPV 53.7% [95% CI: 47.3-60.1], NPV 83.91% [95% CI: 73.2-94.6]). However, these values tended to decrease as the follow-up duration extended, except for the pooled specificities, which exhibited the opposite pattern.

Conclusion: NLR emerges as a simple and cost-effective prognostic biomarker with decent performance for poor outcomes in patients with PAD (PROSPERO Registration No.: CRD42023486607).

背景:中性粒细胞与淋巴细胞比率(NLR中性粒细胞与淋巴细胞比值(NLR)是反映全身炎症(包括外周动脉疾病(PAD))的一个简单而常规的参数:本系统综述旨在评估 NLR 作为 PAD 患者预后生物标志物的作用。我们在 PubMed、ScienceDirect、Web of Science、Scopus、ProQuest、EBSCO 和 Cochrane 上进行了系统检索。采用随机效应荟萃分析法汇集风险比、敏感性、特异性、阳性预测值(PPV)和阴性预测值(NPV)。使用双变量模型生成接收者操作特征概要及相应的曲线下面积(AUC):该研究纳入了九项合格研究中的 5243 名 PAD 患者。高 NLR 意味着全因死亡率(ACM)、主要不良肢体事件(MALE)和主要不良心血管事件(MACE)的风险至少增加两倍。NLR 在预测 1 年 ACM 方面表现良好(AUC 0.71 [95% CI: 0.59-0.79],灵敏度 58.2% [95% CI: 45.3-71.0],特异性 72.6% [95% CI: 65.6-79.62],PPV 41.0% [95% CI: 31.2-50.7],NPV 82.7%[95%CI:74.1-91.3])和 1 年 MALE(AUC 0.78 [95% CI:0.75-0.80],灵敏度 65.4% [95% CI:41.6-89.2],特异性 77.7% [95% CI:71.0-84.3],PPV 53.7% [95% CI:47.3-60.1],NPV 83.91% [95% CI:73.2-94.6])。然而,随着随访时间的延长,这些数值呈下降趋势,但汇总特异性除外,其表现出相反的模式:结论:NLR是一种简单且经济有效的预后生物标志物,对于PAD患者的不良预后具有良好的表现(PROSPERO注册号:CRD42023486607)。
{"title":"Neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with peripheral artery disease: A systematic review and meta-analysis.","authors":"Roy B Kurniawan, Paulus P Siahaan, Pandit Bt Saputra, Jannatin N Arnindita, Cornelia G Savitri, Novia N Faizah, Luqman H Andira, Mario D'Oria, J Nugroho Eko Putranto, Firas F Alkaff","doi":"10.1177/1358863X241281699","DOIUrl":"10.1177/1358863X241281699","url":null,"abstract":"<p><strong>Background: </strong>The neutrophil-to-lymphocyte ratio (NLR) is a simple and routinely obtained parameter reflecting systemic inflammation, including in peripheral artery disease (PAD).</p><p><strong>Methods: </strong>This systematic review aimed to assess the role of NLR as a prognostic biomarker in patients with PAD. A systematic search was conducted across PubMed, ScienceDirect, Web of Science, Scopus, ProQuest, EBSCO, and Cochrane. Random-effects meta-analysis was used to pool risk ratios, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). A bivariate model was used to generate summary receiver operating characteristics with the corresponding area under the curve (AUC).</p><p><strong>Results: </strong>This review included 5243 patients with PAD from nine eligible studies. High NLR corresponded to at least a twofold increased risk of all-cause mortality (ACM), major adverse limb events (MALE), and major adverse cardiovascular events (MACE). NLR's performance was good for predicting 1-year ACM (AUC 0.71 [95% CI: 0.59-0.79], sensitivity 58.2% [95% CI: 45.3-71.0], specificity 72.6% [95% CI: 65.6-79.62], PPV 41.0% [95% CI: 31.2-50.7], NPV 82.7% [95% CI: 74.1-91.3]) and 1-year MALE (AUC 0.78 [95% CI: 0.75-0.80], sensitivity 65.4% [95% CI: 41.6-89.2], specificity 77.7% [95% CI: 71.0-84.3], PPV 53.7% [95% CI: 47.3-60.1], NPV 83.91% [95% CI: 73.2-94.6]). However, these values tended to decrease as the follow-up duration extended, except for the pooled specificities, which exhibited the opposite pattern.</p><p><strong>Conclusion: </strong>NLR emerges as a simple and cost-effective prognostic biomarker with decent performance for poor outcomes in patients with PAD <b>(PROSPERO Registration No.: CRD42023486607)</b>.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"687-699"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11590382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142476010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of incident stroke among individuals without coronary artery calcification: A pooled cohort analysis from the Multi-Ethnic Study of Atherosclerosis, Jackson Heart Study, and Framingham Heart Study. 无冠状动脉钙化者发生中风的预测因素:多种族动脉粥样硬化研究》、《杰克逊心脏研究》和《弗雷明汉心脏研究》的汇总队列分析。
IF 3 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-12-01 Epub Date: 2024-09-06 DOI: 10.1177/1358863X241270911
Aliza Hussain, Michelle C Johansen, Michael J Blaha, Mouaz H Al-Mallah, Miguel Cainzos-Achirica, Vijay Nambi, Jerome I Rotter, Xiuqing Guo, Jie Yao, Stephen S Rich, Jaideep Patel, John W McEvoy, Khurram Nasir, Rebecca Gottesman, Roger S Blumenthal, Christie M Ballantyne, Salim S Virani, Mahmoud Al Rifai

Introduction: The absence of coronary artery calcium (CAC = 0) is associated with low risk of stroke events; however, predictors of incident stroke among those with CAC = 0 are not known.

Methods: Individual participant-level data were pooled from three prospective cohorts (Multi-Ethnic Study of Atherosclerosis [MESA], Jackson Heart Study, and Framingham Heart Study). Multivariable-adjusted Cox proportional hazards models were used to study the association between cardiovascular risk factors and incident adjudicated stroke among individuals with CAC = 0 who were free of clinical atherosclerotic cardiovascular disease at baseline.

Results: Among 6180 participants (mean age 53 [SD 11] years, 62% women, and 44% White, 36% Black, and 20% other individuals), over a median (IQR) follow up of 15 (12-16) years, there were 122 strokes (95 ischemic, 27 hemorrhagic) with an overall unadjusted event rate of 2.0 per 1000 person-years. After multivariable adjustment, risk factors associated with overall stroke included (hazard ratio [95% CI]) systolic blood pressure (SBP): 1.19 (1.05-1.36) per 10-mmHg increase and carotid intima-media thickness (CIMT): 1.21 (1.04-1.42) per 0.1-mm increment. Current cigarette smoking: 2.68 (1.11-6.50), SBP: 1.23 (1.06-1.42) per 10-mmHg increase, and CIMT: 1.25 (1.04-1.49) per 0.1-mm increment were associated with ischemic stroke, whereas C-reactive protein was associated with hemorrhagic stroke risk (0.49, 0.25-0.93).

Conclusion: In a large cohort of individuals with CAC = 0, the rate for incident stroke was low (2.0 per 1000-person years) and was associated with modifiable risk factors.

导言:无冠状动脉钙化(CAC = 0)与中风事件的低风险相关;然而,CAC = 0 患者中发生中风的预测因素尚不清楚:方法:从三个前瞻性队列(多种族动脉粥样硬化研究、杰克逊心脏研究和弗雷明汉心脏研究)中汇集个人参与者水平的数据。采用多变量调整的 Cox 比例危险模型研究基线时无临床动脉粥样硬化性心血管疾病、CAC = 0 的个体的心血管危险因素与判定卒中事件之间的关系:在 6180 名参与者(平均年龄 53 [SD 11] 岁,62% 为女性,44% 为白人,36% 为黑人,20% 为其他人群)中,在中位数(IQR)为 15(12-16)年的随访期间,共发生 122 例中风(95 例缺血性中风,27 例出血性中风),总体未调整事件发生率为 2.0‰。经多变量调整后,与总体中风相关的风险因素包括(危险比 [95% CI])收缩压 (SBP):每增加 10 mmHg 为 1.19(1.05-1.36),颈动脉内膜中层厚度 (CIMT):每增加 10 mmHg 为 1.21(1.04-1.36):每增加 0.1 毫米:1.21(1.04-1.42)。目前吸烟:2.68 (1.11-6.50)、SBP:每增加 10 mmHg 增加 1.23 (1.06-1.42)、CIMT:每增加 0.1 mm 增加 1.25 (1.04-1.49)与缺血性中风相关,而 C 反应蛋白与出血性中风风险相关(0.49, 0.25-0.93):结论:在 CAC = 0 的大型人群中,中风发生率较低(每千人年 2.0 例),且与可改变的风险因素有关。
{"title":"Predictors of incident stroke among individuals without coronary artery calcification: A pooled cohort analysis from the Multi-Ethnic Study of Atherosclerosis, Jackson Heart Study, and Framingham Heart Study.","authors":"Aliza Hussain, Michelle C Johansen, Michael J Blaha, Mouaz H Al-Mallah, Miguel Cainzos-Achirica, Vijay Nambi, Jerome I Rotter, Xiuqing Guo, Jie Yao, Stephen S Rich, Jaideep Patel, John W McEvoy, Khurram Nasir, Rebecca Gottesman, Roger S Blumenthal, Christie M Ballantyne, Salim S Virani, Mahmoud Al Rifai","doi":"10.1177/1358863X241270911","DOIUrl":"10.1177/1358863X241270911","url":null,"abstract":"<p><strong>Introduction: </strong>The absence of coronary artery calcium (CAC = 0) is associated with low risk of stroke events; however, predictors of incident stroke among those with CAC = 0 are not known.</p><p><strong>Methods: </strong>Individual participant-level data were pooled from three prospective cohorts (Multi-Ethnic Study of Atherosclerosis [MESA], Jackson Heart Study, and Framingham Heart Study). Multivariable-adjusted Cox proportional hazards models were used to study the association between cardiovascular risk factors and incident adjudicated stroke among individuals with CAC = 0 who were free of clinical atherosclerotic cardiovascular disease at baseline.</p><p><strong>Results: </strong>Among 6180 participants (mean age 53 [SD 11] years, 62% women, and 44% White, 36% Black, and 20% other individuals), over a median (IQR) follow up of 15 (12-16) years, there were 122 strokes (95 ischemic, 27 hemorrhagic) with an overall unadjusted event rate of 2.0 per 1000 person-years. After multivariable adjustment, risk factors associated with overall stroke included (hazard ratio [95% CI]) systolic blood pressure (SBP): 1.19 (1.05-1.36) per 10-mmHg increase and carotid intima-media thickness (CIMT): 1.21 (1.04-1.42) per 0.1-mm increment. Current cigarette smoking: 2.68 (1.11-6.50), SBP: 1.23 (1.06-1.42) per 10-mmHg increase, and CIMT: 1.25 (1.04-1.49) per 0.1-mm increment were associated with ischemic stroke, whereas C-reactive protein was associated with hemorrhagic stroke risk (0.49, 0.25-0.93).</p><p><strong>Conclusion: </strong>In a large cohort of individuals with CAC = 0, the rate for incident stroke was low (2.0 per 1000-person years) and was associated with modifiable risk factors.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"632-639"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical outcomes in patients with chronic limb-threatening ischemia and infected ulcers following endovascular therapy are pathogen dependent: A single-center experience from 2012 to 2021. 危重肢体缺血和感染性溃疡患者接受血管内治疗后的临床疗效取决于病原体:2012年至2021年的单中心经验。
IF 3 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-12-01 Epub Date: 2024-09-20 DOI: 10.1177/1358863X241268692
Jonas Salm, Franziska Ikker, Tanja Böhme, Elias Noory, Ulrich Beschorner, Tobias Siegfried Kramer, Siegbert Rieg, Dirk Westermann, Thomas Zeller

Background: Patients with chronic limb-threatening ischemia (CLTI) and infected leg ulcers are at risk of amputation and postinterventional sepsis.

Methods: This retrospective, single-center study included patients with CLTI and infected leg ulcers who underwent endovascular treatment (EVT) between 2012 and 2021.

Results: The study included 712 patients, 286 (40.2%) of whom underwent amputation (minor, n = 212; major, n = 74). Gram-negative bacteria (GNB) were significantly more prevalent in amputees (36.4% vs 30.9%, p < 0.05). Patients with gram-positive bacteria (GPB) had a 4-year freedom from any amputation rate of 72% (95% CI 64-81%) compared to 52% (95% CI 42-66%) in patients with GNB identification (p < 0.05). Cox proportional regression analysis showed that GNB, male sex, mean Wound, Ischemia, and foot Infection (WIfI) score, diabetes mellitus, and end-stage renal disease were independently and positively associated with amputation (p < 0.05). The mean WIfI score and end-stage renal disease were independently and positively associated with death from any cause (p < 0.05). Staphylococcus aureus or GNB, end-stage renal disease, and diabetes mellitus were independent risk factors for sepsis after EVT (p < 0.05). Inpatient-administered antibiotic regimes had significantly higher microbiological activity in cases of GPB identification compared to GNB identification (28% vs 9%, p < 0.05).

Conclusion: Although the isolation of both GNB and S. aureus is a risk factor for sepsis following EVT, the isolation of GNB is independently associated with higher rates of amputation, demonstrating the importance of identifying pathogens to recognize patients at high risk.

背景:危重肢体缺血(CLTI)和感染性腿部溃疡患者面临截肢和介入治疗后败血症的风险:危重肢体缺血(CLTI)和感染性腿部溃疡患者有截肢和介入治疗后败血症的风险:这项回顾性单中心研究纳入了2012年至2021年期间接受血管内治疗(EVT)的CLTI和感染性腿部溃疡患者:研究纳入了712名患者,其中286人(40.2%)接受了截肢手术(小截肢,212人;大截肢,74人)。革兰氏阴性菌(GNB)在截肢患者中的感染率明显更高(36.4% vs 30.9%,P < 0.05)。革兰氏阳性菌(GPB)患者的 4 年免截肢率为 72%(95% CI 64-81%),而 GNB 患者的 4 年免截肢率为 52%(95% CI 42-66%)(P < 0.05)。Cox 比例回归分析显示,GNB、男性、平均伤口、缺血和足部感染(WIfI)评分、糖尿病和终末期肾病与截肢呈独立正相关(P < 0.05)。WIfI 平均得分和终末期肾病与任何原因导致的死亡均呈独立正相关(P < 0.05)。金黄色葡萄球菌或 GNB、终末期肾病和糖尿病是 EVT 后发生败血症的独立风险因素(P < 0.05)。与GNB鉴定相比,住院患者使用的抗生素方案在GPB鉴定病例中的微生物活性明显更高(28% vs 9%,P < 0.05):结论:尽管分离出 GNB 和金黄色葡萄球菌都是 EVT 术后脓毒症的风险因素,但分离出 GNB 单独与较高的截肢率相关,这表明识别病原体对识别高风险患者的重要性。
{"title":"Clinical outcomes in patients with chronic limb-threatening ischemia and infected ulcers following endovascular therapy are pathogen dependent: A single-center experience from 2012 to 2021.","authors":"Jonas Salm, Franziska Ikker, Tanja Böhme, Elias Noory, Ulrich Beschorner, Tobias Siegfried Kramer, Siegbert Rieg, Dirk Westermann, Thomas Zeller","doi":"10.1177/1358863X241268692","DOIUrl":"10.1177/1358863X241268692","url":null,"abstract":"<p><strong>Background: </strong>Patients with chronic limb-threatening ischemia (CLTI) and infected leg ulcers are at risk of amputation and postinterventional sepsis.</p><p><strong>Methods: </strong>This retrospective, single-center study included patients with CLTI and infected leg ulcers who underwent endovascular treatment (EVT) between 2012 and 2021.</p><p><strong>Results: </strong>The study included 712 patients, 286 (40.2%) of whom underwent amputation (minor, <i>n</i> = 212; major, <i>n</i> = 74). Gram-negative bacteria (GNB) were significantly more prevalent in amputees (36.4% vs 30.9%, <i>p</i> < 0.05). Patients with gram-positive bacteria (GPB) had a 4-year freedom from any amputation rate of 72% (95% CI 64-81%) compared to 52% (95% CI 42-66%) in patients with GNB identification (<i>p</i> < 0.05). Cox proportional regression analysis showed that GNB, male sex, mean Wound, Ischemia, and foot Infection (WIfI) score, diabetes mellitus, and end-stage renal disease were independently and positively associated with amputation (<i>p</i> < 0.05). The mean WIfI score and end-stage renal disease were independently and positively associated with death from any cause (<i>p</i> < 0.05). <i>Staphylococcus aureus</i> or GNB, end-stage renal disease, and diabetes mellitus were independent risk factors for sepsis after EVT (<i>p</i> < 0.05). Inpatient-administered antibiotic regimes had significantly higher microbiological activity in cases of GPB identification compared to GNB identification (28% vs 9%, <i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Although the isolation of both GNB and <i>S. aureus</i> is a risk factor for sepsis following EVT, the isolation of GNB is independently associated with higher rates of amputation, demonstrating the importance of identifying pathogens to recognize patients at high risk.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"700-706"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subclinical coronary artery disease and perioperative cardiac events in patients undergoing peripheral artery bypass surgery. 接受外周动脉搭桥手术患者的亚临床冠状动脉疾病和围手术期心脏事件。
IF 3 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-12-01 Epub Date: 2024-09-25 DOI: 10.1177/1358863X241280070
Abiah Pritchard, Nichole Brunton, Swapna Sharma, Michael N Young, Stanislav Henkin
{"title":"Subclinical coronary artery disease and perioperative cardiac events in patients undergoing peripheral artery bypass surgery.","authors":"Abiah Pritchard, Nichole Brunton, Swapna Sharma, Michael N Young, Stanislav Henkin","doi":"10.1177/1358863X241280070","DOIUrl":"10.1177/1358863X241280070","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"720-722"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vascular Disease Patient Information Page: Erythromelalgia. 血管疾病患者信息页面:红斑性肢痛症
IF 3 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-12-01 Epub Date: 2024-10-08 DOI: 10.1177/1358863X241285533
Elizabeth V Ratchford, Alexandra L Solomon, Mark Dp Davis
{"title":"Vascular Disease Patient Information Page: Erythromelalgia.","authors":"Elizabeth V Ratchford, Alexandra L Solomon, Mark Dp Davis","doi":"10.1177/1358863X241285533","DOIUrl":"10.1177/1358863X241285533","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"735-738"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Images in Vascular Medicine: Analysis of skin microvascular dysfunction in Harlequin syndrome using laser speckle contrast imaging. 血管医学图像:利用激光斑点对比成像分析哈勒金综合征的皮肤微血管功能障碍。
IF 3 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-12-01 Epub Date: 2024-10-16 DOI: 10.1177/1358863X241279570
Alicia Guigui, Géraldine Dumas, Matthieu Roustit, Sophie Blaise
{"title":"Images in Vascular Medicine: Analysis of skin microvascular dysfunction in Harlequin syndrome using laser speckle contrast imaging.","authors":"Alicia Guigui, Géraldine Dumas, Matthieu Roustit, Sophie Blaise","doi":"10.1177/1358863X241279570","DOIUrl":"10.1177/1358863X241279570","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"733-734"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142476009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in patient characteristics and mortality among Medicare patients diagnosed with peripheral artery disease. 被诊断患有外周动脉疾病的医疗保险患者的特征和死亡率趋势。
IF 3 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-12-01 Epub Date: 2024-09-09 DOI: 10.1177/1358863X241262330
Xavier Fowler, Kunal Mehta, Mark Eid, Barbara Gladders, Stephen Kearing, Kayla O Moore, Mark A Creager, Andrea M Austin, Mark W Feinberg, Marc P Bonaca, Philip Greenland, Mary M McDermott, Philip P Goodney

Introduction: Peripheral artery disease (PAD) is a well-described risk factor for mortality, but few studies have examined secular trends in mortality over time for patients with PAD. We characterized trends in mortality in patients with PAD in recent years among Medicare patients.

Methods: We used Medicare claims to identify patients with a new diagnosis code for PAD between January 1, 2006 and December 31, 2018 using International Classification of Diseases (ICD) diagnosis codes. The primary outcome of interest was the 1-year all-cause age-adjusted mortality rate. Our secondary outcome was the 5-year all-cause mortality rate. Multivariable regression was used to identify factors which predict mortality at 1 year.

Results: We identified 4,373,644 patients with a new diagnosis code for PAD during the study period. Between 2006 and 2018, 1-year all-cause age-adjusted mortality declined from 12.6% to 9.9% (p < 0.001). One-year crude all-cause mortality also declined from 14.6% to 9.5% (p < 0.001). Similar results were observed for 5-year age-adjusted mortality rates (40.9% to 35.2%, p < 0.001). Factors associated with increased risk of death at 1 year included age ⩾ 85 years (hazard ratio [HR] 3.030; 95% CI 3.008-3.053) and congestive heart failure (HR 1.86; 95% CI 1.85-1.88). Patients who were regularly dispensed statins, ace-inhibitors, beta-blockers, antithrombotic agents, and anticoagulants all had lower mortality (range OR 0.36; CI 0.35-0.37 for statins to OR 0.60; CI 0.59-0.61 for anticoagulants; all p < 0.001).

Conclusion: Among US Medicare patients diagnosed with PAD between 2006 and 2019, 1-year age-adjusted mortality declined by 2.7%. This decline in mortality among patients with PAD occurred in the context of a younger mean age of diagnosis of PAD and improved cardiovascular prevention therapy.

简介:外周动脉疾病(PAD)是一种公认的死亡风险因素,但很少有研究调查 PAD 患者死亡率的长期趋势。我们描述了近年来医疗保险(Medicare)患者中 PAD 患者的死亡率趋势:我们利用医疗保险报销单,使用国际疾病分类(ICD)诊断代码识别了 2006 年 1 月 1 日至 2018 年 12 月 31 日期间有 PAD 新诊断代码的患者。我们关注的主要结果是 1 年全因年龄调整后死亡率。我们的次要结果是 5 年全因死亡率。多变量回归用于确定预测 1 年死亡率的因素:在研究期间,我们确定了 4,373,644 名新诊断代码为 PAD 的患者。2006 年至 2018 年间,经年龄调整后的 1 年全因死亡率从 12.6% 降至 9.9%(p < 0.001)。1年粗略全因死亡率也从14.6%降至9.5%(p < 0.001)。经年龄调整后的 5 年死亡率也出现了类似的结果(从 40.9% 降至 35.2%,p < 0.001)。与 1 年死亡风险增加相关的因素包括年龄⩾ 85 岁(危险比 [HR] 3.030;95% CI 3.008-3.053)和充血性心力衰竭(HR 1.86;95% CI 1.85-1.88)。定期服用他汀类药物、王牌抑制剂、β-受体阻滞剂、抗血栓药和抗凝剂的患者死亡率均较低(他汀类药物的OR值为0.36;CI值为0.35-0.37,抗凝剂的OR值为0.60;CI值为0.59-0.61;所有P均小于0.001):在2006年至2019年期间被诊断为PAD的美国医疗保险患者中,经年龄调整后的1年死亡率下降了2.7%。PAD患者死亡率的下降是在PAD诊断平均年龄年轻化和心血管预防治疗得到改善的背景下发生的。
{"title":"Trends in patient characteristics and mortality among Medicare patients diagnosed with peripheral artery disease.","authors":"Xavier Fowler, Kunal Mehta, Mark Eid, Barbara Gladders, Stephen Kearing, Kayla O Moore, Mark A Creager, Andrea M Austin, Mark W Feinberg, Marc P Bonaca, Philip Greenland, Mary M McDermott, Philip P Goodney","doi":"10.1177/1358863X241262330","DOIUrl":"10.1177/1358863X241262330","url":null,"abstract":"<p><strong>Introduction: </strong>Peripheral artery disease (PAD) is a well-described risk factor for mortality, but few studies have examined secular trends in mortality over time for patients with PAD. We characterized trends in mortality in patients with PAD in recent years among Medicare patients.</p><p><strong>Methods: </strong>We used Medicare claims to identify patients with a new diagnosis code for PAD between January 1, 2006 and December 31, 2018 using International Classification of Diseases (ICD) diagnosis codes. The primary outcome of interest was the 1-year all-cause age-adjusted mortality rate. Our secondary outcome was the 5-year all-cause mortality rate. Multivariable regression was used to identify factors which predict mortality at 1 year.</p><p><strong>Results: </strong>We identified 4,373,644 patients with a new diagnosis code for PAD during the study period. Between 2006 and 2018, 1-year all-cause age-adjusted mortality declined from 12.6% to 9.9% (<i>p</i> < 0.001). One-year crude all-cause mortality also declined from 14.6% to 9.5% (<i>p</i> < 0.001). Similar results were observed for 5-year age-adjusted mortality rates (40.9% to 35.2%, <i>p</i> < 0.001). Factors associated with increased risk of death at 1 year included age ⩾ 85 years (hazard ratio [HR] 3.030; 95% CI 3.008-3.053) and congestive heart failure (HR 1.86; 95% CI 1.85-1.88). Patients who were regularly dispensed statins, ace-inhibitors, beta-blockers, antithrombotic agents, and anticoagulants all had lower mortality (range OR 0.36; CI 0.35-0.37 for statins to OR 0.60; CI 0.59-0.61 for anticoagulants; all <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Among US Medicare patients diagnosed with PAD between 2006 and 2019, 1-year age-adjusted mortality declined by 2.7%. This decline in mortality among patients with PAD occurred in the context of a younger mean age of diagnosis of PAD and improved cardiovascular prevention therapy.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"653-663"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Procedural interventions for erythromelalgia: A narrative review. 红斑性肢痛症的手术干预:叙述性综述。
IF 3 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-12-01 Epub Date: 2024-09-25 DOI: 10.1177/1358863X241279427
Jinnee Uj Lee, Janice E Ma, Julio C Sartori Valinotti, Thom W Rooke, Paola Sandroni, James C Watson, Mark Dp Davis

Erythromelalgia is a rare disorder characterized by episodic burning pain with redness and warmth of the extremities. Topical and systemic medications are the mainstay of management. We reviewed the published evidence for using procedural interventions to manage erythromelalgia, including their proposed mechanism of action and possible adverse effects, and included information in this review on epidural infusion, sympathetic ganglion block, sympathectomy, pulsed radiofrequency, spinal cord stimulation, dorsal root ganglion stimulation, brain stimulation, transcranial magnetic stimulation, and botulinum toxin injections. Both successful and unsuccessful outcomes have been reported. Although these procedural interventions extend the therapeutic options for erythromelalgia, the evidence for their use is limited. Case reports and small case series comprise most of the evidence. Based on our review, a multidisciplinary approach to management may be needed for patients with erythromelalgia.

红斑性肢痛症是一种罕见的疾病,以阵发性灼痛、四肢发红和发热为特征。局部和全身用药是治疗的主要方法。我们回顾了已发表的使用程序性干预治疗红斑性肢痛症的证据,包括它们的作用机制和可能的不良反应,并将硬膜外输液、交感神经节阻滞、交感神经切除术、脉冲射频、脊髓刺激、背根神经节刺激、脑刺激、经颅磁刺激和肉毒毒素注射的相关信息纳入本综述。成功和失败的结果都有报道。虽然这些程序性干预扩大了红斑性肢痛症的治疗选择范围,但使用这些疗法的证据却很有限。大部分证据都是病例报告和小型病例系列。根据我们的综述,红斑性肢痛症患者可能需要采用多学科方法进行治疗。
{"title":"Procedural interventions for erythromelalgia: A narrative review.","authors":"Jinnee Uj Lee, Janice E Ma, Julio C Sartori Valinotti, Thom W Rooke, Paola Sandroni, James C Watson, Mark Dp Davis","doi":"10.1177/1358863X241279427","DOIUrl":"10.1177/1358863X241279427","url":null,"abstract":"<p><p>Erythromelalgia is a rare disorder characterized by episodic burning pain with redness and warmth of the extremities. Topical and systemic medications are the mainstay of management. We reviewed the published evidence for using procedural interventions to manage erythromelalgia, including their proposed mechanism of action and possible adverse effects, and included information in this review on epidural infusion, sympathetic ganglion block, sympathectomy, pulsed radiofrequency, spinal cord stimulation, dorsal root ganglion stimulation, brain stimulation, transcranial magnetic stimulation, and botulinum toxin injections. Both successful and unsuccessful outcomes have been reported. Although these procedural interventions extend the therapeutic options for erythromelalgia, the evidence for their use is limited. Case reports and small case series comprise most of the evidence. Based on our review, a multidisciplinary approach to management may be needed for patients with erythromelalgia.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"723-732"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2023-24 Reviewer and Guest Editor Acknowledgements. 2023-24 审稿人和特约编辑致谢。
IF 3 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-12-01 Epub Date: 2024-10-14 DOI: 10.1177/1358863X241291659
{"title":"2023-24 Reviewer and Guest Editor Acknowledgements.","authors":"","doi":"10.1177/1358863X241291659","DOIUrl":"https://doi.org/10.1177/1358863X241291659","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":"29 6","pages":"748-750"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlights from the 2024 SVM Vascular Scientific Sessions. 2024 年 SVM 血管科学会议要点。
IF 3 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-12-01 Epub Date: 2024-10-30 DOI: 10.1177/1358863X241294061
Elizabeth V Ratchford
{"title":"Highlights from the 2024 SVM Vascular Scientific Sessions.","authors":"Elizabeth V Ratchford","doi":"10.1177/1358863X241294061","DOIUrl":"10.1177/1358863X241294061","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"739-747"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Vascular Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1